[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol; 2006 Mar;59(3):490-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of hamartomas in multiple organs.
  • Five to 15% of affected individuals display subependymal giant cell astrocytomas, which can lead to substantial neurological and postoperative morbidity due to the production of hydrocephalus, mass effect, and their typical location adjacent to the foramen of Monro.
  • METHODS: Five subjects with clinically definite TSC and either subependymal giant cell astrocytomas (n = 4) or a pilocytic astrocytoma (n = 1) were treated with oral rapamycin at standard immunosuppressive doses (serum levels 5-15 ng/ml) from 2.5 to 20 months.
  • All lesions demonstrated growth on serial neuroimaging studies.
  • RESULTS: All lesions exhibited regression and, in one case, necrosis.
  • Interruption of therapy resulted in regrowth of subependymal giant cell astrocytomas in one patient.
  • INTERPRETATION: Oral rapamycin therapy can induce regression of astrocytomas associated with TSC and may offer an alternative to operative therapy of these lesions.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / etiology. Brain Neoplasms / drug therapy. Immunosuppressive Agents. Regression (Psychology). Sirolimus / therapeutic use. Tuberous Sclerosis / complications
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Humans. Magnetic Resonance Imaging / methods. Male. Models, Biological


2. Wen PY: American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther; 2010 Sep;10(9):1367-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.
  • A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting.
  • There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas.
  • Other studies focused on promising new agents such as XL184 and ANG1005.
  • [MeSH-major] Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Immunosuppressive Agents / therapeutic use. Sirolimus / analogs & derivatives. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Aged. Clinical Trials as Topic. Everolimus. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans

  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836670.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Clinical Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


3. Ohgaki H, Kim YH, Steinbach JP: Nervous system tumors associated with familial tumor syndromes. Curr Opin Neurol; 2010 Dec;23(6):583-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nervous system tumors associated with familial tumor syndromes.
  • Signaling pathways involved in hereditary syndromes predisposing to the development of nervous system tumors include RAS, WNT, RB1, TP53, and PTCH signaling pathways, which play key roles in gene regulation, apoptosis, and cell proliferation.
  • The discovery of the genetic origin of nervous system tumors in patients with familial cancer syndromes has been the basis for target identification and drug development.
  • We also briefly review two important advances in this area: the treatment of medulloblastomas in patients with mutations in the PTCH1 gene, and the discovery of deregulated mammalian target of rapamycin as a major oncogenic driver molecule in patients with TSC mutations and subependymal giant cell astrocytoma.
  • SUMMARY: Progress in the understanding of hereditary nervous system tumors is increasingly important for diagnosis and treatment.
  • [MeSH-major] Genetic Diseases, Inborn / diagnosis. Genetic Diseases, Inborn / genetics. Genetic Predisposition to Disease / genetics. Nervous System Neoplasms / diagnosis. Nervous System Neoplasms / genetics
  • [MeSH-minor] Child. Humans. Medulloblastoma / diagnosis. Medulloblastoma / genetics. Medulloblastoma / metabolism. Signal Transduction / genetics. Syndrome. Tuberous Sclerosis / diagnosis. Tuberous Sclerosis / genetics. Tuberous Sclerosis / metabolism


Advertisement
4. McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH: Gaboxadol, a selective extrasynaptic GABA(A) agonist, does not generalise to other sleep-enhancing drugs: a rat drug discrimination study. Neuropharmacology; 2007 Mar;52(3):844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gaboxadol, a selective extrasynaptic GABA(A) agonist, does not generalise to other sleep-enhancing drugs: a rat drug discrimination study.
  • Gaboxadol is a selective extrasynaptic GABA(A) receptor agonist (SEGA) which enhances slow-wave sleep, and may act principally at extrasynaptic GABA(A)alpha4betadelta receptors.
  • Drug discrimination is a very useful approach for exploring in vivo pharmacological similarities and differences between compounds and was therefore used to compare gaboxadol and zolpidem, an established hypnotic drug, against zopiclone, S-zopiclone, indiplon and tiagabine, all of which have been reported to enhance sleep.
  • Gaboxadol and tiagabine each have a different discriminative stimulus from all the other drugs tested.
  • [MeSH-major] Discrimination Learning / drug effects. GABA Agonists / pharmacology. Generalization (Psychology) / drug effects. Isoxazoles / pharmacology. Sleep / drug effects
  • [MeSH-minor] Animals. Conditioning, Operant / drug effects. Dose-Response Relationship, Drug. Drug Evaluation. Drug Interactions. Male. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196996.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / Isoxazoles; K1M5RVL18S / gaboxadol
  •  go-up   go-down


5. Walsh JK, Deacon S, Dijk DJ, Lundahl J: The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep; 2007 May;30(5):593-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVES: Evaluate the hypnotic efficacy of gaboxadol, a selective extrasynaptic GABAA agonist (SEGA), in a phase advance model of transient insomnia.
  • Neither drug treatment was associated with residual effects the morning after treatment.
  • These differences may reflect the different mechanisms of action of the two drugs.
  • [MeSH-major] GABA Agonists / therapeutic use. GABA-A Receptor Agonists. Hypnotics and Sedatives / therapeutic use. Isoxazoles / therapeutic use. Sleep / drug effects
  • [MeSH-minor] Adolescent. Adult. Cross-Over Studies. Delta Rhythm. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Male. Middle Aged. Polysomnography. Pyridines / therapeutic use. Sleep, REM / drug effects. Theta Rhythm. Wakefulness / drug effects

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552374.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / GABA-A Receptor Agonists; 0 / Hypnotics and Sedatives; 0 / Isoxazoles; 0 / Pyridines; 7K383OQI23 / zolpidem; K1M5RVL18S / gaboxadol
  •  go-up   go-down


6. Walsh JK, Mayleben D, Guico-Pabia C, Vandormael K, Martinez R, Deacon S: Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial. Sleep Med; 2008 May;9(4):393-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The hypnotic efficacy of gaboxadol, a selective extrasynaptic GABA A agonist (SEGA), was evaluated in a phase-advance model of transient insomnia.
  • [MeSH-major] GABA Agonists / therapeutic use. Isoxazoles / therapeutic use. Polysomnography / drug effects. Receptors, GABA / drug effects. Sleep Initiation and Maintenance Disorders / drug therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Male. Middle Aged. Wakefulness / drug effects

  • MedlinePlus Health Information. consumer health - Insomnia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765013.001).
  • [ISSN] 1389-9457
  • [Journal-full-title] Sleep medicine
  • [ISO-abbreviation] Sleep Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00102167
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / Isoxazoles; 0 / Receptors, GABA; K1M5RVL18S / gaboxadol
  •  go-up   go-down


7. Koenig MK, Butler IJ, Northrup H: Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol; 2008 Oct;23(10):1238-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.
  • The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas.

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] BMC Dermatol. 2008;8:1 [18226258.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • (PMID = 18952591.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024149; United States / NCRR NIH HHS / RR / RR024149-05S1; United States / NCRR NIH HHS / RR / KL2 RR024149-05S1
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS282750; NLM/ PMC3072698
  •  go-up   go-down


8. Ebert B, Wafford KA, Deacon S: Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther; 2006 Dec;112(3):612-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating insomnia: Current and investigational pharmacological approaches.
  • Current pharmacological approaches focus primarily on GABA, the major inhibitory neurotransmitter in the central nervous system.
  • Variations in GABA(A) receptor subunit composition confer unique pharmacological, biophysical, and electrophysiological properties on each receptor subtype.
  • Gaboxadol, an investigational treatment and a selective extrasynaptic GABA(A) receptor agonist (SEGA), targets GABA(A) receptors containing a delta subunit, which are located outside the synaptic junctions of thalamic and cortical neurons thought to play an important regulatory role in the onset, maintenance, and depth of the sleep process.
  • [MeSH-major] Hypnotics and Sedatives / therapeutic use. Sleep Initiation and Maintenance Disorders / drug therapy
  • [MeSH-minor] Animals. Electroencephalography / drug effects. GABA-A Receptor Agonists. Humans. Receptors, Melatonin / agonists. Serotonin Antagonists / pharmacology. Serotonin Antagonists / therapeutic use. Sleep / drug effects. Sleep / physiology. gamma-Aminobutyric Acid / physiology

  • MedlinePlus Health Information. consumer health - Insomnia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876255.001).
  • [ISSN] 0163-7258
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GABA-A Receptor Agonists; 0 / Hypnotics and Sedatives; 0 / Receptors, Melatonin; 0 / Serotonin Antagonists; 56-12-2 / gamma-Aminobutyric Acid
  • [Number-of-references] 660
  •  go-up   go-down


9. Hajak G, Hedner J, Eglin M, Loft H, Stórustovu SI, Lütolf S, Lundahl J, Gaboxadol Study 99775 Group: A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients. Sleep Med; 2009 Aug;10(7):705-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the efficacy and safety profile of gaboxadol, a selective extrasynaptic GABA(A) agonist (SEGA) previously in development for the treatment of insomnia.
  • METHODS: This was a randomised, double-blind, placebo-controlled, parallel-group, 2-week, Phase III study of gaboxadol 5, 10 and 15mg in outpatients meeting the DSM-IV criteria of primary insomnia (N=742).
  • [MeSH-major] Ambulatory Care. Automatic Data Processing. GABA Agonists / adverse effects. Isoxazoles / adverse effects. Pyridines / adverse effects. Sleep Initiation and Maintenance Disorders / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnostic and Statistical Manual of Mental Disorders. Double-Blind Method. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Severity of Illness Index. Single-Blind Method. Substance Withdrawal Syndrome / etiology. Surveys and Questionnaires. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Insomnia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346160.001).
  • [ISSN] 1878-5506
  • [Journal-full-title] Sleep medicine
  • [ISO-abbreviation] Sleep Med.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GABA Agonists; 0 / Isoxazoles; 0 / Pyridines; 7K383OQI23 / zolpidem; K1M5RVL18S / gaboxadol
  • [Investigator] Saletu-Zyhlarz G; Schmitz MM; Högl BE; de Volder I; Dumont F; Theys P; Herchuelz A; Matte R; Morehouse R; Lespérance P; Rajda M; Pawluk L; George CF; Morán M; Sonka K; Jennum P; Wildschiødtz G; Sørensen KV; Hion T; Partinen MM; Polo OJ; Mehtonen OP; Dauvilliers Y; Tiberge M; Leger D; Lainey E; Escourrou P; Schenk C; Kölmel HW; Wiegand M; Benes H; Hajak G; Hemmeter UM; Steinberg R; Cirignotta F; Gigli GL; Smits MG; de Weerd AW; Bjorvatn B; Lundemo G; Tvedten T; Eldøen G; Jernajczyk W; Myszka DM; Jakitowicz J; Lewandowski S; Borreguero DG; Estivill E; Sagalés T; Cuartero P; Pin G; Paniagua J; Cañellas F; Mejuto J; Hedner J; Ulfberg J; Hemlin M; Grote L; Despland PA; Holsboer E; Fisch HU; Nutt D; James IG; Soul P; Smith I; Ebrahim IO; Silvert BD
  •  go-up   go-down


10. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med; 2010 Nov 4;363(19):1801-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
  • BACKGROUND: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex.
  • An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.
  • METHODS: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study.
  • The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months.
  • Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%).
  • There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma.
  • CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Seizures / drug therapy. Sirolimus / analogs & derivatives. Tuberous Sclerosis / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Angiofibroma / drug therapy. Anticonvulsants / therapeutic use. Child. Child, Preschool. Cognition / drug effects. Drug Therapy, Combination. Everolimus. Facial Neoplasms / drug therapy. Female. Humans. Male. Prospective Studies. Quality of Life. TOR Serine-Threonine Kinases. Young Adult


11. Jufe GS: [New hypnotics: perspectives from sleep physiology]. Vertex; 2007 Jul-Aug;18(74):294-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insomnia is a disorder that affects a large part of the population.
  • Agents that are used to treat this sleep disorder have evolved: benzodiazepines replaced barbiturates, but there is still concern about their residual effects and about the development of dependence and the risk of withdrawal symptoms.
  • Currently the benzodiazepines receptor agonists (zolpidem, zaleplon, zopiclone and eszopiclone) are the agents most widely prescribed.
  • Pharmaceutical technology and the advances in the knowledge of sleep physiology have led to the availability of some novelties like modified release zolpidem (indicated not only to initiate but also to maintain sleep., ramelteon and agomelatine (melatonine receptors agonists).
  • This article summarises these subjects as well as the pharmacology of investigational drugs, such as indiplon (another benzodiazepine receptor agonist), gaboxadol ( a selective extrasynaptic GABAA agonist -SEGA-), and some anticonvulsant drugs that could be useful as hypnotics: tiagabine ( a GABA transporter inhibitor), pregabaline and gabapentine (GABA analogs).
  • [MeSH-minor] Humans. Melatonin / physiology. Receptors, GABA / drug effects. Receptors, GABA / physiology

  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265473.001).
  • [ISSN] 0327-6139
  • [Journal-full-title] Vertex (Buenos Aires, Argentina)
  • [ISO-abbreviation] Vertex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; 0 / Receptors, GABA; JL5DK93RCL / Melatonin
  • [Number-of-references] 15
  •  go-up   go-down






Advertisement